Digital Content 
NEWS #PharmaBuzz
01 Apr 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/yingli-pharma-announces-successful-end-of-phase-2-meeting-with-fda-and-clearance-of-global-multi-center-phase-3-registration-study-design-of-linperlisib-for-the-treatment-of-relapsed-andor-refractory-peripheral-t-cell-lymphoma-302416397.html
11 Dec 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/yingli-pharma-presents-a-pivotal-phase-2-study-data-evaluating-linperlisib-in-relapsed-or-refractory-peripheral-t-cell-lymphoma-in-an-oral-session-at-the-american-society-of-hematology-2023-annual-meeting-302010879.html
10 Jun 2021
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/yingli-pharma-announces-a-presentation-on-the-phase-2-clinical-trial-of-linperlisib-a-pi3k-selective-inhibitor-in-relapsed-or-refractory-follicular-lymphoma-at-the-european-hematology-association-2021-congress-301310715.html
10 Jun 2021
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/yingli-pharma-announces-a-presentation-on-the-phase-2-clinical-trial-of-linperlisib-a-pi3k-selective-inhibitor-in-relapsed-or-refractory-follicular-lymphoma-at-the-european-hematology-association-2021-congress-301310715.html
10 Jun 2021
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/yingli-pharma-announces-a-presentation-on-the-phase-2-clinical-trial-of-linperlisib-a-pi3k-selective-inhibitor-in-relapsed-or-refractory-follicular-lymphoma-at-the-european-hematology-association-2021-congress-301310715.html
10 Jun 2021
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/yingli-pharma-announces-a-presentation-on-the-phase-2-clinical-trial-of-linperlisib-a-pi3k-selective-inhibitor-in-relapsed-or-refractory-follicular-lymphoma-at-the-european-hematology-association-2021-congress-301310715.html
Share 